Quest Diagnostics Incorporated

NYSE:DGX Stock Report

Market Cap: US$25.5b

Quest Diagnostics Future Growth

Future criteria checks 1/6

Quest Diagnostics is forecast to grow earnings and revenue by 9.8% and 4.4% per annum respectively. EPS is expected to grow by 9.6% per annum. Return on equity is forecast to be 16.1% in 3 years.

Key information

9.8%

Earnings growth rate

9.61%

EPS growth rate

Healthcare earnings growth17.3%
Revenue growth rate4.4%
Future return on equity16.05%
Analyst coverage

Good

Last updated08 Sep 2026

Recent future growth updates

Analysis Article • Jul 26

Earnings Beat: Quest Diagnostics Incorporated Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Quest Diagnostics Incorporated ( NYSE:DGX ) defied analyst predictions to release its second-quarter results, which...

Recent updates

Narrative Update • Aug 08

DGX: Advanced Testing Expansion And Guidance Raise Will Support Balanced Outlook

Analysts have raised their blended price target for Quest Diagnostics from about $239 to roughly $246, citing recent Q2 beats, refreshed models, and expanding testing offerings in areas such as Alzheimer's disease, autoimmune conditions, and early cancer detection. Analyst Commentary Street research on Quest Diagnostics points to a generally constructive tone after Q2, with most firms lifting their price targets and refining models to reflect recent results and updated guidance.
Analysis Article • Jul 26

Earnings Beat: Quest Diagnostics Incorporated Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Quest Diagnostics Incorporated ( NYSE:DGX ) defied analyst predictions to release its second-quarter results, which...
Narrative Update • Jul 25

DGX: Advanced Diagnostics And AI Progress Will Support Balanced Risk Reward Profile

The analyst price target for Quest Diagnostics has been raised from $223.44 to $239.38, reflecting updated views that recent Q2 beats, higher guidance, and ongoing organic growth can support slightly stronger profit margins while keeping a similar P/E framework in place. Analyst Commentary Recent research on Quest Diagnostics points to a generally constructive stance, with most price targets moving higher after the Q2 report.
Seeking Alpha • Jul 24

Quest Diagnostics Upgrades EPS Outlook For 2026 After Outperforming Q2 Results

Summary Quest Diagnostics earns a reiterated buy rating after Q2 earnings beat, upgraded FY guidance, and continued market momentum. DGX benefits from strong macro demand for specialized diagnostic testing, peer-leading ROE, and resilient top-line growth (+10.2% YoY). Upward earnings revisions, robust dividend growth, and investment-grade credit ratings support the bull case, though cost pressures and payor risk warrant monitoring. Valuation shows some opportunity, but total return forecast falls short of hurdle rate; sector-specific regulatory risks remain a challenge. Read the full article on Seeking Alpha
Analysis Article • Jun 21

Quest Diagnostics (DGX) Stock Could Be 12.7% Below Fair Value on Testing Growth Narrative

Recent Share Performance and Business Scale Quest Diagnostics (DGX) has seen its stock decline about 1.4% over the past day and roughly 4% over the past week, while returns over the past month and past 3 months are close to flat. Despite these short term moves, the company operates at considerable scale, with revenue of about $11.3b and net income of roughly $1.0b, and a market value near $21.6b based on the latest figures. See our latest analysis for Quest Diagnostics. At a share price of...
Narrative Update • Jun 18

DGX: Advanced Diagnostics And AI Execution Will Support Safe Haven Appeal

Analysts have nudged their blended price targets on Quest Diagnostics higher, with a series of $5 to $20 upward revisions from multiple firms helping to justify only marginal tweaks to the model inputs and leaving the fair value estimate essentially unchanged at about $223.44 per share. Analyst Commentary Recent research on Quest Diagnostics clusters around a constructive stance, with several firms lifting price targets in increments of US$5 to US$20 while leaving underlying estimates and the blended fair value near US$223.44 per share.
Narrative Update • Jun 04

DGX: Raised 2026 Guidance And Execution Strength Will Sustain Safe Haven Appeal

Quest Diagnostics' analyst price target nudged up by about $0.19 to roughly $223.44 as analysts fine-tuned assumptions around the discount rate, revenue growth, profit margins, and future P/E, following a series of recent target increases across major research firms. Analyst Commentary Recent research has converged around higher price targets for Quest Diagnostics, with several firms adjusting their models and one firm previously cutting its target while keeping a more tactical positive stance.
Narrative Update • May 13

DGX: Refreshed 2026 Outlook And Margin Assumptions Will Sustain Safe Haven Appeal

Quest Diagnostics' analyst price target has been revised to $223.25 from $218.19 as analysts factor in recent target increases across the Street and updated assumptions around discount rate, profit margins and future P/E multiples. Analyst Commentary Recent Street research around Quest Diagnostics has centered on refreshed valuation work and price target changes, with several firms adjusting their numbers based on updated assumptions for discount rates, profit margins and future P/E multiples.
Narrative Update • Apr 20

DGX: Organic Guidance And Capital Returns Will Sustain Safe Haven Appeal

Analyst price targets for Quest Diagnostics have been adjusted slightly lower to $218.19 from $218.50, as analysts factor in updated views on revenue growth, profit margins, and long term P/E assumptions following a series of recent target changes across the coverage universe. Analyst Commentary Recent research updates point to a mixed but generally constructive stance on Quest Diagnostics, with multiple target changes and one fresh list inclusion helping to frame how analysts are thinking about valuation, execution, and growth risk.
Narrative Update • Apr 05

DGX: Organic Guidance And Capital Returns Will Support Safe Haven Profile

Analysts have raised their price targets on Quest Diagnostics by between $5 and $30, largely pointing to recently issued organic revenue growth guidance and viewing the broader diagnostic lab space as a relative safe haven within healthcare services. Analyst Commentary Recent Street research around Quest Diagnostics and its closest peer highlights a constructive setup for the broader diagnostic lab group, with price target moves on Quest generally framed against views that the sector can act as a relative safe haven within healthcare services.
Narrative Update • Mar 22

DGX: Premium Multiple And Capital Returns Look Supported By Organic Revenue Guidance

Analysts have raised their price targets on Quest Diagnostics by a range of $5 to $30, citing the company’s recent organic revenue growth guidance and viewing the diagnostic testing space as a relative safe haven within healthcare services. Analyst Commentary Recent research on Quest Diagnostics highlights a cluster of higher price targets and an upgrade, with many investors treating large diagnostic labs as a relatively defensive corner of healthcare services.
Narrative Update • Mar 07

DGX: Fair Outlook As Premium Multiple And Capital Returns Shape Future Earnings

Analysts raised their price target on Quest Diagnostics by about $1 to $218.50, reflecting refined assumptions that include slightly higher revenue growth, a similar discount rate, modestly adjusted profit margins, and a small change in future P/E expectations, supported by broadly positive recent research across the diagnostic lab space. Analyst Commentary Street research around Quest Diagnostics has focused on how the company is positioned within the broader diagnostic lab group, with recent moves in peer guidance and a series of price target changes shaping sentiment on both upside potential and execution risk.
Narrative Update • Feb 21

DGX: Fair Outlook As Higher Payouts And Consumer Labs Support Future Earnings

Analysts have lifted their price target on Quest Diagnostics by about $18, reflecting slightly higher modeled revenue growth and a somewhat richer future P/E assumption, even as projected profit margins are trimmed in line with recent Street research that has broadly raised targets across the lab testing group. Analyst Commentary Bullish analysts have broadly raised their price targets on Quest Diagnostics, reflecting a more constructive view on the lab testing group as a whole and on Quest's positioning within it.
Narrative Update • Feb 06

DGX: Fair Outlook As Consumer Lab Partnerships And Margins Support Future Earnings

Analysts have inched up their fair value estimate for Quest Diagnostics to about $199 per share, a move they tie to slightly higher margin and P/E assumptions following recent research that points to potential upside to current earnings estimates. Analyst Commentary Recent Street research points to potential upside to current earnings estimates for Quest Diagnostics, which is feeding into a more constructive view on the stock’s valuation and execution risk.
Narrative Update • Jan 23

DGX: Future Consumer Lab Partnerships And Neurology Tests Will Support Balanced Outlook

Analysts have inched up their price target on Quest Diagnostics to about $198.38 from roughly $198.06, reflecting refreshed assumptions around slightly higher revenue growth, a small adjustment to profit margins, and a near steady forward P/E outlook. What's in the News Hims & Hers Health is offering lab testing that it views as a potential US$1b business, with customers accessing testing through Quest Diagnostics and then receiving results and care plans through the Hims platform (Wall Street Journal).
Narrative Update • Jan 06

DGX: Future Lab Partnerships And Testing Pipeline Will Support Bullish Outlook

Analysts lifted their price target for Quest Diagnostics by about US$1 to roughly US$198, citing recent Q3 results with sales and earnings ahead of consensus; raised full year guidance; firm organic volume trends; and growing interest in longer term opportunities, such as the Haystack MRD test and a generally supportive lab testing backdrop. Analyst Commentary Street research following the Q3 report points to a generally constructive tone, with multiple firms lifting their price targets and highlighting both execution on current fundamentals and potential longer term growth drivers.
Narrative Update • Dec 14

DGX: Future Lab Partnerships And Testing Pipeline Will Support Balanced Outlook

Analysts have nudged their price targets on Quest Diagnostics higher by between $5 and $25 per share, citing solid Q3 outperformance, raised guidance, and confidence in organic growth and future testing catalysts. Analyst Commentary Street research following the Q3 print highlights a generally constructive stance on Quest Diagnostics, with most price target increases framed around stronger than expected fundamentals and improving visibility into growth drivers over the next two years.
Narrative Update • Nov 29

DGX: Future Volume Gains And Lab Partnerships Will Support Balanced Outlook

The analyst price target for Quest Diagnostics was modestly increased to $197.31 from $197.25. Analysts cited stronger-than-expected earnings, raised guidance, and continued positive core trends as the rationale for the update.
Narrative Update • Nov 15

DGX: Future Revenue Expansion And Partnerships Will Balance Near-Term Risks

Quest Diagnostics saw its analyst price target increase, with several firms now projecting new targets between $195 and $215 per share. Analysts cite strong quarterly results and ongoing positive momentum in core business trends.
Narrative Update • Nov 01

DGX: Core Volume Momentum And New Blood Tests Will Drive Share Momentum

Quest Diagnostics' analyst fair value estimate has been raised from $191.56 to $197.25 per share. This change reflects analysts' upbeat outlook after strong quarterly results, improved profit margins, and continued momentum in core business trends.
Narrative Update • Oct 18

Preventive Diagnostics And Automation Will Shape Future Healthcare

Analysts have raised their fair value estimate for Quest Diagnostics from $188.19 to $191.56 per share, citing ongoing stable end markets and improving revenue growth expectations. Analyst Commentary Recent street research has highlighted a mix of optimism and caution surrounding Quest Diagnostics.

Earnings and Revenue Growth Forecasts

NYSE:DGX - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202813,0881,3491,4352,98210
12/31/202712,5701,2351,3292,18815
12/31/202612,0071,1461,2272,07915
6/30/202611,5601,0581,3491,903N/A
3/31/202611,2781,0201,3261,850N/A
12/31/202511,0359881,3591,886N/A
9/30/202510,8509631,3931,885N/A
6/30/202510,5229451,2241,678N/A
3/31/202510,1588921,0561,494N/A
12/31/20249,8728669091,334N/A
9/30/20249,5398381,0231,397N/A
6/30/20249,3468368751,248N/A
3/31/20249,2878429471,332N/A
12/31/20239,2528508641,272N/A
9/30/20239,2977595961,079N/A
6/30/20239,4887908781,374N/A
3/31/20239,6037898641,332N/A
12/31/20229,8839421,3141,718N/A
9/30/202210,2941,2301,4641,865N/A
6/30/202210,5821,4791,5521,924N/A
3/31/202210,6791,8741,6021,982N/A
12/31/202110,7881,9881,8302,233N/A
9/30/202111,0462,1751,8722,293N/A
6/30/202111,0582,2382,1712,594N/A
3/31/202110,3351,7942,0682,489N/A
12/31/20209,4371,4251,5872,005N/A
9/30/20208,3611,1011,3841,812N/A
6/30/20207,5317498161,249N/A
3/31/20207,657771N/A1,215N/A
12/31/20197,726835N/A1,243N/A
9/30/20197,639709N/A1,190N/A
6/30/20197,572707N/A1,293N/A
3/31/20197,538720N/A1,295N/A
12/31/20187,531733N/A1,200N/A
9/30/20187,557860N/A1,228N/A
6/30/20187,524808N/A1,188N/A
3/31/20187,469782N/A1,159N/A
12/31/20177,402769N/A1,175N/A
9/30/20177,398671N/A1,156N/A
6/30/20177,427701N/A1,095N/A
3/31/20177,469702N/A1,112N/A
12/31/20167,214642N/A1,116N/A
9/30/20167,503675N/A1,037N/A
6/30/20167,498825N/A948N/A
3/31/20167,517748N/A922N/A
12/31/20157,493706N/A821N/A
9/30/20157,527703N/A852N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: DGX's forecast earnings growth (9.8% per year) is above the savings rate (3.7%).

Earnings vs Market: DGX's earnings (9.8% per year) are forecast to grow slower than the US market (17.3% per year).

High Growth Earnings: DGX's earnings are forecast to grow, but not significantly.

Revenue vs Market: DGX's revenue (4.4% per year) is forecast to grow slower than the US market (13.5% per year).

High Growth Revenue: DGX's revenue (4.4% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: DGX's Return on Equity is forecast to be low in 3 years time (16.1%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/11 22:54
End of Day Share Price 2026/09/11 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Quest Diagnostics Incorporated is covered by 37 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jasper HellwegArgus Research Company
Eric ColdwellBaird
Adam FeinsteinBarclays